<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-37055" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Fluorescein</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Pothen</surname>
            <given-names>Amy-Grace</given-names>
          </name>
          <aff>Nova Southeastern University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Parmar</surname>
            <given-names>Mayur</given-names>
          </name>
          <aff>Nova Southeastern University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Amy-Grace Pothen declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mayur Parmar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>29</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-37055.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Fluorescein is a diagnostic contrast agent particularly used in various ophthalmic procedures, such as checking for any corneal or vessel abnormalities. The application of fluorescein also extends to bioimaging whole anatomic structures and even further to cellular components in immunohistological staining. This article outlines the indications, mechanism of action, adverse event profile, and contraindications for fluorescein to guide the healthcare team in evaluating ophthalmic abnormalities, infection, and pathophysiology, among other conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of fluorescein.</p></list-item><list-item><p>Describe the possible adverse effects of fluorescein.</p></list-item><list-item><p>Review the appropriate monitoring for patients receiving fluorescein.</p></list-item><list-item><p>Summarize interprofessional team strategies for improving care coordination and communication to advance fluorescein and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=37055&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=37055">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-37055.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Fluorescein is an organic compound used as a dye, particularly as a fluorescent agent in diagnostic procedures at various levels.</p>
        <p>
<bold>Ophthalmology</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Fluorescein has extensive use in routine ophthalmic tests. This usage ranges from applanation tonometry, gonioscopy, and contact lens fittings to angioscopy/angiography of retina and iris vasculature. In the first scenario, after an anesthetic and a fluorescein strip are applied to the eyes, a tonometer is placed on the cornea to determine the intraocular pressure of one eye at a time. Applanation tonometry utilizes fluorescein to produce semicircles that aid in the measurement of the dial reading. For improved detection of any breaks in the vasculature or associated retinal conditions, fluorescein angiography stains the blood vessels of the retina and iris to provide a detailed image of the posterior view of the eye. One study on retinopathy of prematurity (ROP) relies on fluorescein angiography to evaluate treatment efficacy between two different drugs on peripheral retina vasculature. Unlike plain fundus photographs, fluorescein angiography also pinpointed vascular loops, blunting, dilatation, and capillary dropout.<xref ref-type="bibr" rid="article-37055.r1">[1]</xref><xref ref-type="bibr" rid="article-37055.r2">[2]</xref><xref ref-type="bibr" rid="article-37055.r1">[1]</xref></p>
          </list-item>
          <list-item>
            <p>Additionally, fluorescein produces remarkable contrast to determine if any corneal abrasions, corneal perforations, epithelial keratitis, herpes simplex keratitis, or corneal foreign bodies are present. If the cornea is not intact, aqueous humor leaks through and mixes with the fluorescein dye to reveal a corneal perforation. In a study assessing dry eyes, fluorescein was useful in measuring the stability of the tear film. Despite any significant differences between using a standard strip or small volumes of liquid dye, fluorescein proved effective in augmenting any breaks in the tear film that occurs in dry eye disease.<xref ref-type="bibr" rid="article-37055.r3">[3]</xref><xref ref-type="bibr" rid="article-37055.r4">[4]</xref><xref ref-type="bibr" rid="article-37055.r3">[3]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Bioimaging&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>The remarkable fluorescence of fluorescein permits considerable insight into the identification of non-diseased tissues, tumor-affected tissues, or histological markers. For example, fluorescein can serve as a contrast agent in surgical procedures for nonspecific identification of anatomic arrangements. Fluorescence of healthy tissue of the focused region differentiates it from nearby normal tissues and aids the surgeon in removing or repairing necessary tissues while also protecting vital structures. A surgery&#x000a0;to repair hand anatomy may need fluorescein to highlight the nerves specific for fine motor skills or differentiate the blood vessels of a particular section.<xref ref-type="bibr" rid="article-37055.r5">[5]</xref></p>
          </list-item>
          <list-item>
            <p>Furthermore, in a microendoscopy study to find dysplasia in colorectal tissue, fluorescein was preferred to proflavine, especially due to its ability to highlight crypt structures with greater sensitivity, intensity, and uniformity. Identification of structures on a deeper, finer level expands the nonspecific functionality of fluorescein and eases the process of diagnostic procedures.<xref ref-type="bibr" rid="article-37055.r6">[6]</xref> Its range of use can be from a bundle of nerves to an individual blood vessel, further&#x000a0;to&#x000a0;tissue abnormalities,&#x000a0;and even further to the molecular level.</p>
          </list-item>
        </list>
        <p>
<bold>Conjugate Species/Biomarker</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Fluorescent microscopy allows for the identification of microorganisms or cellular components, such as proteins, in immunohistological staining. In the most common indirect method of immunohistochemistry, the enzyme-linked immunosorbent assay (ELISA) uses fluorescein to act as a fluorescent conjugated to secondary antibodies. Moreover, certain compounds commonly modify or combine with the original fluorescein structure to adjust the attachment of the fluorescent tag to specific macromolecules. The combination of water-soluble chitosan derivative with a fluorescent tag created glycol chitosan fluorescein-isothiocyanate (GC-FITC), which showed to be a sufficient agent used for bio-imaging when compared to its commercial equivalents. Even at a lower concentration, the biocompatibility of the molecule, as well as the strong affinity to the cell surface through a strong electrostatic interaction, offer efficient cell staining, namely for the identification of lipid rafts.<xref ref-type="bibr" rid="article-37055.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p>On a clinical level, a cardiology study exhibits the use of fluorescein as a fluorescent tag/biomarker in cardioscopy for the detection/monitoring of coronary artery disease (CAD). Fluorescein is injected into the circulatory system, and its fluorescence is observable throughout cardiomyocytes in terms of tissue fluid flow. Through molecular bioimaging, fluorescein plays a role in the status of patients with CAD experiencing angina pectoris or other cardiovascular issues or who have undergone treatment with stents.<xref ref-type="bibr" rid="article-37055.r8">[8]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-37055.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>As an ocular disclosing agent, fluorescein sodium dissolves readily in aqueous alkaline solutions, responds to 465 to 490 nm at cobalt blue light, and fluoresces at 520 to 530 nm as bright green. The compound contains a conjugated system that illuminates when electrons spend a prolonged time in an excited state. It is often administered in combination with a local anesthetic such as proparacaine or benoxinate, which inhibits sodium ion channels to stabilize nerve cell membranes to inhibit nerve impulse conduction.</p>
        <p>When using fluorescein to stain cells, its charged ends become attracted to the hydrophilic ends in the cell membrane to form a strong electrostatic bond. One or more of the charged ends of fluorescein may then be modified for greater interaction.<xref ref-type="bibr" rid="article-37055.r7">[7]</xref></p>
      </sec>
      <sec id="article-37055.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Ophthalmic administration of fluorescein starts with a paper strip with one tip stained with fluorescein. The paper strip is moistened with saline water and then placed on the conjunctiva or inferior fornix. The patient may blink a few times to spread the dye across the eye.</p>
        <p>For ocular foreign body removal, the clinician should instill 1 or 2 drops in the eyes pre-procedural.</p>
        <p>Fluorescein solution may be administered orally and requires 10&#x000a0;to 15 minutes before appearing. Although the solution is bitter, combining it with sugar or a beverage can increase palatability.</p>
        <p>Intravenous injection of fluorescein sodium occurs at the antecubital vein. The dye appears almost immediately in the retina and choroidal vessels (in 7 to 14 seconds). In the case of anaphylaxis, IV access is still necessary for epinephrine.&#x000a0;</p>
        <p>After the administration of fluorescein, the examiner can extinguish the room light to view the fluorescence of the dye under cobalt blue light.<xref ref-type="bibr" rid="article-37055.r9">[9]</xref></p>
      </sec>
      <sec id="article-37055.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Common: paresthesia of lips, change in taste (orally), severe eye-stinging and irritation (ophthalmic), severe nausea, vomiting, abdominal pain, chest pain, and extravasation.</p>
        <list list-type="bullet">
          <list-item>
            <p>Mild: urine discoloration, skin inflammation/discoloration at the injection site&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Moderate: rashes, urticaria, syncope/dizziness/hypotension, angioedema, chest pain</p>
          </list-item>
          <list-item>
            <p>Severe: nerve palsy, seizure, bronchospasm, pulmonary edema, epithelial keratopathy, anaphylaxis<xref ref-type="bibr" rid="article-37055.r9">[9]</xref></p>
          </list-item>
        </list>
        <p>Corneal opacification can occur with prolonged use.</p>
      </sec>
      <sec id="article-37055.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Hypersensitivity to fluorescein formulation prevents its application. Furthermore, even though more research is needed to determine side effects on a fetus, pregnancy may be considered a relative contraindication, although based on the drug's pharmacology and limited systemic absorption, no fetal harm is expected.<xref ref-type="bibr" rid="article-37055.r9">[9]</xref>&#x000a0;Likewise, the drug may be used during breastfeeding even in the absence of any human data, as no harm to the infant or impact on maternal milk production is expected based on pharmacological properties.</p>
        <p>If the formulation includes an ester anesthetic, as is often the case, hypersensitivity to such agents is also a contraindication. Other contraindications include sensitivity to PABA (para-aminobenzoic acid) and prolonged use.</p>
      </sec>
      <sec id="article-37055.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Fluorescein has no known significant drug interactions. Under ophthalmic examination, contact lens removal is necessary with the use of fluorescein to avoid unnecessary staining.<xref ref-type="bibr" rid="article-37055.r2">[2]</xref> Fluorescein completely clears through urine excretion 2&#x000a0;to 3 days after injection.<xref ref-type="bibr" rid="article-37055.r9">[9]</xref>&#x000a0;There are no recommended routine tests or lab values.</p>
      </sec>
      <sec id="article-37055.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Fluorescein toxicity is low. Proper doses of epinephrine and antihistamines can manage cases of significant hypersensitivity after flushing the affected area with plenty of water. Prevention of anaphylaxis is possible by providing a minimal dose of fluorescein to determine if a minor reaction would occur.</p>
        <p>If enough fluorescein is issued intravenously, precaution&#x000a0;is necessary for nursing mothers because another route of excretion is through human milk, causing it to turn yellow.<xref ref-type="bibr" rid="article-37055.r10">[10]</xref></p>
      </sec>
      <sec id="article-37055.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Because fluorescein administration is for diagnostic purposes, its use is most commonly by specialists,&#x000a0;especially ophthalmologists, and surgeons, as well as optometrists,&#x000a0;but it is also used by&#x000a0;general practitioners, including physicians, nurse practitioners, and physician assistants. Nurses and/or medical assistants may also assess the proper dosage for the desired procedure. Not all health professionals readily operate with a fluorescent agent. Nurses can assist in the procedure via preparation, monitoring for adverse effects, and post-procedural care. Interprofessional coordination between the various members of the healthcare team will result in optimal results when using fluorescein for diagnostic purposes, which in turn can lead to appropriate therapeutic intervention and improved patient outcomes. [Level 5]</p>
      </sec>
      <sec id="article-37055.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=37055&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=37055">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/37055/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=37055">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-37055.s11">
        <title>References</title>
        <ref id="article-37055.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Yin</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Gui</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>XX</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Fluorescein Angiographic Findings of Peripheral Retinal Vasculature after Intravitreal Conbercept versus Ranibizumab for Retinopathy of Prematurity.</article-title>
            <source>J Ophthalmol</source>
            <year>2019</year>
            <volume>2019</volume>
            <fpage>3935945</fpage>
            <pub-id pub-id-type="pmid">31976086</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37055.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fern&#x000e1;ndez-Jimenez</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Diz-Arias</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Peral</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Improving ocular surface comfort in contact lens wearers.</article-title>
            <source>Cont Lens Anterior Eye</source>
            <year>2022</year>
            <month>Jun</month>
            <volume>45</volume>
            <issue>3</issue>
            <fpage>101544</fpage>
            <pub-id pub-id-type="pmid">34840071</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37055.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paugh</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Tse</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sasai</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>De Jesus</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Kwan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Farid</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Garg</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jester</surname>
                <given-names>JV</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of the Fluorescein Tear Breakup Time Test in Dry Eye.</article-title>
            <source>Cornea</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>39</volume>
            <issue>1</issue>
            <fpage>92</fpage>
            <page-range>92-98</page-range>
            <pub-id pub-id-type="pmid">31513046</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37055.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Naik</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Magdum</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ahuja</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kaul</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>S</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mishra</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Patil</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dhore</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Alapati</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Ocular Surface Diseases in Patients With Diabetes.</article-title>
            <source>Cureus</source>
            <year>2022</year>
            <month>Mar</month>
            <volume>14</volume>
            <issue>3</issue>
            <fpage>e23401</fpage>
            <pub-id pub-id-type="pmid">35495002</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37055.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Orosco</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Tsien</surname>
                <given-names>RY</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>QT</given-names>
              </name>
            </person-group>
            <article-title>Fluorescence imaging in surgery.</article-title>
            <source>IEEE Rev Biomed Eng</source>
            <year>2013</year>
            <volume>6</volume>
            <fpage>178</fpage>
            <page-range>178-87</page-range>
            <pub-id pub-id-type="pmid">23335674</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37055.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prieto</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Lai</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Laryea</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Mizell</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Mustain</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Muldoon</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>Fluorescein as a topical fluorescent contrast agent for quantitative microendoscopic inspection of colorectal epithelium.</article-title>
            <source>Biomed Opt Express</source>
            <year>2017</year>
            <month>Apr</month>
            <day>01</day>
            <volume>8</volume>
            <issue>4</issue>
            <fpage>2324</fpage>
            <page-range>2324-2338</page-range>
            <pub-id pub-id-type="pmid">28736674</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37055.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>WH</given-names>
              </name>
            </person-group>
            <article-title>Fluorescent property of glycol chitosan-fluorescein isothiocyanate conjugate for bio-imaging material.</article-title>
            <source>Int J Biol Macromol</source>
            <year>2019</year>
            <month>Aug</month>
            <day>15</day>
            <volume>135</volume>
            <fpage>1217</fpage>
            <page-range>1217-1221</page-range>
            <pub-id pub-id-type="pmid">31181277</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37055.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Uchida</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Uchida</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Dye-Staining Angioscopy for Coronary Artery Disease.</article-title>
            <source>Curr Cardiovasc Imaging Rep</source>
            <year>2015</year>
            <volume>8</volume>
            <issue>4</issue>
            <fpage>10</fpage>
            <pub-id pub-id-type="pmid">25750692</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37055.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kornblau</surname>
                <given-names>IS</given-names>
              </name>
              <name>
                <surname>El-Annan</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>Adverse reactions to fluorescein angiography: A comprehensive review of the literature.</article-title>
            <source>Surv Ophthalmol</source>
            <year>2019</year>
            <season>Sep-Oct</season>
            <volume>64</volume>
            <issue>5</issue>
            <fpage>679</fpage>
            <page-range>679-693</page-range>
            <pub-id pub-id-type="pmid">30772364</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37055.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Samples</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Use of ophthalmic medications in pregnant and nursing women.</article-title>
            <source>Am J Ophthalmol</source>
            <year>1988</year>
            <month>Nov</month>
            <day>15</day>
            <volume>106</volume>
            <issue>5</issue>
            <fpage>616</fpage>
            <page-range>616-23</page-range>
            <pub-id pub-id-type="pmid">2903673</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
